Genetic Signatures (ASX:GSS) - Aandelenkoers, Nieuws & Analyse

GSS Overzicht aandelen

Genetic Signatures Limited is actief als moleculair diagnostisch bedrijf in Australië, Azië en de Pacific, Europa, het Midden-Oosten, Azië en Noord- en Zuid-Amerika. Meer informatie

GSS fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	6/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 84% onder onze schatting van de reële waarde

De winst zal naar verwachting met 98.62% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Genetic Signatures Limited Concurrenten

Proteomics International Laboratories

ASX:PIQ

AU$89.1m

Trajan Group Holdings

ASX:TRJ

AU$155.3m

EZZ Life Science Holdings

ASX:EZZ

AU$127.5m

Cryosite

ASX:CTE

AU$43.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Genetic Signatures
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.72
52 Week Hoogtepunt	AU$0.85
52 Week Laag	AU$0.38
Bèta	0.054
11 maand verandering	12.11%
3 maanden verandering	1.06%
1 Jaar Verandering	44.95%
33 jaar verandering	-42.37%
5 jaar verandering	-34.77%
Verandering sinds IPO	47.94%

Recent nieuws en updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

Recent updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Nov 14

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Oct 10

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Jun 29

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 28

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

Feb 25

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

Feb 07

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Jan 17

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

Dec 27

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

Dec 06

Rendement voor aandeelhouders

	GSS	AU Life Sciences	AU Markt
7D	0.3%	-6.0%	1.5%
1Y	44.9%	11.8%	17.2%

Rendement versus industrie: GSS overtrof de Australian Life Sciences industrie, die het afgelopen jaar een rendement 11.8 % opleverde.

Rendement versus markt: GSS overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 17.2 %.

Prijsvolatiliteit

Is GSS's price volatile compared to industry and market?
GSS volatility
GSS Average Weekly Movement	6.6%
Life Sciences Industry Average Movement	11.2%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stabiele aandelenkoers: GSS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van GSS is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2001	n/a	Allison Rossiter	www.geneticsignatures.com

Genetic Signatures Limited is actief als moleculair diagnostisch bedrijf in Australië, Azië-Pacific, Europa, het Midden-Oosten, Azië en Noord- en Zuid-Amerika. Het bedrijf biedt darmbacteriën, enteroaggregatieve E.coli aggR en aaiC, enterische virussen, enterische protozoën, enterische protozoën uitgebreid, enterische microsporidia, respiratoire pathogenen, SARS-CoV-2, SARS-CoV-2 respiratoir plus, coronavirus, atypische respiratoire, pertussis en PCP, parainfluenza 4, soa genitale pathogenen, breedspectrum beta-lactamase en carbapenemase producerende organismen, virale meningitis, flavivirus dengue alfavirus, flavivirus reflex, dengue typering en alfavirus reflex Detectiekits onder de naam EasyScreen. Genetic Signatures Limited werd opgericht in 2001 en het hoofdkantoor is gevestigd in Newtown, Australië.

Genetic Signatures Limited Samenvatting

Hoe verhouden de winst en inkomsten van Genetic Signatures zich tot de beurswaarde?
GSS fundamentele statistieken
Marktkapitalisatie	AU$158.81m
Inkomsten(TTM)	-AU$17.86m
Inkomsten(TTM)	AU$13.77m

11.8x

P/S-verhouding

-9.1x

Koers/Winstverhouding

Is GSS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GSS resultatenrekening (TTM)
Inkomsten	AU$13.77m
Kosten van inkomsten	AU$7.91m
Brutowinst	AU$5.86m
Overige uitgaven	AU$23.72m
Inkomsten	-AU$17.86m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.079
Brutomarge	42.53%
Nettowinstmarge	-129.74%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde GSS op de lange termijn?

Bekijk historische prestaties en vergelijking

GSS Overzicht aandelen

Beloningen

Risicoanalyse

Genetic Signatures Limited Concurrenten

ASX:PIQ

AU$89.1m

ASX:TRJ

AU$155.3m

ASX:EZZ

AU$127.5m

ASX:CTE

AU$43.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 60%

Full year 2024 earnings: EPS misses analyst expectations

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Recent updates

Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 60%

Full year 2024 earnings: EPS misses analyst expectations

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Consensus revenue estimates fall by 28%

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Consensus revenue estimates decrease by 31%

New minor risk - Shareholder dilution

Genetic Signatures Limited has filed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Price target decreased by 20% to AU$0.90

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Now 21% undervalued after recent price drop

Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022)

New minor risk - Financial data availability

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022)

Less than half of directors are independent

Price target decreased to AU$0.90

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021)

Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Price target decreased to AU$1.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues exceed analyst expectations

Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples

Full year 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to AU$2.20

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall to AU$28.0m

New 90-day low: AU$1.58

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020)

Revenue beats expectations, earnings disappoint

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: AU$1.65

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

New 90-day low - AU$1.95

Full year earnings released - AU$0.016 loss per share

New 90-day high - AU$2.62

Rendement voor aandeelhouders